Related Experiment Videos
[Enoximone--clinical experiences in heart surgery]
A D Krüger1, A Francke, K Emmrich
1Klinik und Poliklinik für Anästhesiologie und Intensivtherapie, Medizinischen Fakultät, Universität Rostock.
Anaesthesiologie Und Reanimation
|January 1, 1996
Summary
Enoximone effectively treats cardiac low-output syndrome post-cardiac surgery, especially when combined with beta-sympathomimetics. Its vasodilating effects require careful management with volume and alpha-mimetic support.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Cardiac low-output syndrome is a critical complication following valve replacement and coronary bypass grafting.
- Management of hemodynamics in early post-cardiac surgery is crucial for patient outcomes.
Purpose:
- To evaluate the efficacy of enoximone, a phosphodiesterase-III-inhibitor, in treating cardiac low-output syndromes post-cardiac surgery.
- To assess the hemodynamic effects and optimal use of enoximone in conjunction with other કાર્ડियोactive agents.
Summary:
- Enoximone demonstrated significant importance in managing cardiac low-output syndrome, particularly in patients with preoperative myocardial compromise.
- Combination therapy with beta-sympathomimetics enhanced enoximone's inotropic effect via dual cAMP elevation.
- While effective in increasing cardiac index, enoximone's vasodilatory action necessitated supportive measures like volume loading and alpha-mimetic agents, especially after valve replacement.
Impact:
- Enoximone offers a valuable therapeutic option for early post-cardiac surgery low-output states, improving short-term outcomes.
- Understanding enoximone's hemodynamic profile aids in optimizing its use and managing potential complications.
- This study highlights the need for tailored hemodynamic management strategies based on surgical procedure and patient condition.